新一代肿瘤标志物循环肿瘤细胞的研究进展

doi:10.13481/j.1671-587x.20200338

摘要/Abstract

摘要： 循环肿瘤细胞（CTCs）是存在于肿瘤患者血液中有活性的肿瘤细胞，与恶性肿瘤的复发和转移关系密切。随着多种检测技术和分析方法的发展，对CTCs的认识不断深入。CTCs检测对获取肿瘤细胞信息较组织活检更方便，目前已经越来越多地将其应用于恶性肿瘤的辅助诊断和指导治疗。以患者少量外周血为标本检测CTCs作为液体活检的方式之一，可实现对肿瘤的病理诊断；CTCs数与肿瘤分期、抗肿瘤治疗疗效、复发风险和患者生存期密切相关；对CTCs进行分子和基因水平分析可评估病情发展、指导临床精准治疗，并最终改善患者总生存时间（OS），是新一代的肿瘤标志物。现就CTCs的生物学特性、检测方法和临床应用的研究进展进行简要综述。

关键词: 肿瘤, 循环肿瘤细胞, 肿瘤复发, 肿瘤转移, 精准治疗

中图分类号:

陈菲, 周小越, 白日兰, 崔久嵬. 新一代肿瘤标志物循环肿瘤细胞的研究进展[J]. 吉林大学学报(医学版), 2020, 46(03): 662-667.

参考文献

[1] 李健斌, 江泽飞. 循环肿瘤细胞研究进展:从计数到表型的转变[J].中华肿瘤杂志, 2016, 38(12):881-885.
[2] CHAFFER C L, SAN JUAN B P, LIM E, et al. EMT, cell plasticity and metastasis[J]. Cancer Metastasis Rev, 2016, 35(4):645-654.
[3] MARRINUCCI D, BETHEL K, BRUCE R H, et al. Case study of the morphologic variation of circulating tumor cells[J]. Hum Pathol, 2007, 38(3):514-519.
[4] CHEUNG K J, EWALD A J. A collective route to metastasis:Seeding by tumor cell clusters[J]. Science, 2016, 352(6282):167-169.
[5] SKUBITZ A P, TARAS E P, BOYLAN K L, et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression[J]. Gynecol Oncol, 2013, 130(3):579-587.
[6] MAO S F, ZHANG Q, LI H F, et al. Adhesion analysis of single circulating tumor cells on a base layer of endothelial cells using open microfluidics[J]. Chem Sci, 2018, 9(39):7694-7699.
[7] KROG B L, HENRY M D. Biomechanics of the circulating tumor cell microenvironment[J]. Adv Exp Med Biol, 2018, 1092:209-233.
[8] LIBERKO M, KOLOSTOVA K, BOBEK V. Essentials of circulating tumor cells for clinical research and practice[J]. Crit Rev Oncol Hematol, 2013, 88(2):338-356.
[9] SOLER A, CAYREFOURCQ L, MAZARD T, et al. Autologous cell lines from circulating colon cancer cells captured from sequential liquid biopsies as model to study therapy-driven tumor changes[J]. Sci Rep, 2018, 8(1):15931.
[10] FABISIEWICZ A, GRZYBOWSKA E. CTC clusters in cancer progression and metastasis[J]. Med Oncol, 2017, 34(1):12.
[11] VAN ES N, STURK A, MIDDELDORP S, et al. Effects of cancer on platelets[J]. Semin Oncol, 2014, 41(3):311-318.
[12] AMIRKHOSRAVI A, MOUSA S A, AMAYA M, et al. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpⅡb/Ⅲa antagonist XV454[J]. Thromb Haemost, 2003, 90(3):549-554.
[13] FELDING-HABERMANN B, HABERMANN R, SALDIVAR E, et al. Role of beta3 integrins in melanoma cell adhesion to activated platelets under flow[J]. J Biol Chem, 1996, 271(10):5892-5900.
[14] YIE S M, LUO B, YE N Y, et al. Detection of Survivin-expressing circulating cancer cells in the peripheral blood of breast cancer patients by a RT-PCR ELISA[J]. Clin Exp Metastasis, 2006, 23(5/6):279-289.
[15] VEGRAN F, BOIDOT R. Survivin-3B promotes chemoresistance and immune escape by inhibiting caspase-8 and -6 in cancer cells[J]. Oncoimmunology, 2013, 2(11):e26328.
[16] SAKAGUCHI S, YAMAGUCHI T, NOMURA T, et al. Regulatory T cells and immune tolerance[J]. Cell, 2008, 133(5):775-787.
[17] CHOI J, SUH B, AHN Y O, et al. CD15+/CD16 low human granulocytes from terminal cancer patients:granulocytic myeloid-derived suppressor cells that have suppressive function[J]. Tumour Biol, 2012, 33(1):121-129.
[18] XU J M, ZHANG Y, JIA R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer:an open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2):515-523.
[19] GASCOYNE P R, NOSHARI J, ANDERSON T J, et al. Isolation of rare cells from cell mixtures by dielectrophoresis[J]. Electrophoresis, 2009, 30(8):1388-1398.
[20] LIU Z X, GUO W X, ZHANG D D, et al. Circulating tumor cell detection in hepatocellular carcinoma based on karyoplasmic ratios using imaging flow cytometry[J]. Sci Rep, 2016, 6:39808.
[21] HAROUAKA R A, ZHOU M D, YEH Y T, et al. Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells[J]. Clin Chem, 2014, 60(2):323-333.
[22] SARIOGLU A F, ACETO N, KOJIC N, et al. A microfluidic device for label-free, physical capture of circulating tumor cell clusters[J]. Nat Methods, 2015, 12(7):685-691.
[23] CHEN L J, PENG M, LI N, et al. Combined use of EpCAM and FRα enables the high-efficiency capture of circulating tumor cells in non-small cell lung cancer[J]. Sci Rep, 2018, 8(1):1188.
[24] ZHANG Y J, WANG F, NING N, et al. Patterns of circulating tumor cells identified by CEP8, CK and CD45 in pancreatic cancer[J]. Int J Cancer, 2015, 136(5):1228-1233.
[25] GOODALE D, PHAY C, POSTENKA C O, et al. Characterization of tumor cell dissemination patterns in preclinical models of cancer metastasis using flow cytometry and laser scanning cytometry[J]. Cytometry A, 2009, 75(4):344-355.
[26] ANDREE K C, VAN DALUM G, TERSTAPPEN L W. Challenges in circulating tumor cell detection by the cell search system[J]. Mol Oncol, 2016, 10(3):395-407.
[27] SEQUIST L V, NAGRATH S, TONER M, et al. The CTC-chip:an exciting new tool to detect circulating tumor cells in lung cancer patients[J]. J Thorac Oncol, 2009, 4(3):281-283.
[28] STUTTERHEIM J, ICHOU F A, DEN OUDEN E, et al. Methylated RASSF1a is the first specific DNA marker for minimal residual disease testing in neuroblastoma[J]. Clin Cancer Res, 2012, 18(3):808-814.
[29] EBERWINE J, SUL J Y, BARTFAI T, et al. The promise of single-cell sequencing[J]. Nat Methods, 2014, 11(1):25-27.
[30] RAGHUNATHAN A, FERGUSON H R, BORNARTH C J, et al. Genomic DNA amplification from a single bacterium[J]. Appl Environ Microbiol, 2005, 71(6):3342-3347.
[31] ZONG C H, LU S J, CHAPMAN A R, et al. Genome-wide detection of single-nucleotide and copy-number variations of a single human cell[J]. Science, 2012, 338(6114):1622-1626.
[32] JIANG R Z, LU Y T, HO H, et al. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer[J]. Oncotarget, 2015, 6(42):44781-44793.
[33] GAO Y Y, ZHU YY, ZHANG Z Z, et al. Clinical significance of pancreatic circulating tumor cells using combined negative enrichment and immunostaining-fluorescence in situ hybridization[J]. J Exp Clin Cancer Res, 2016, 35:66.
[34] ILIE M, HOFMAN V, LONG-MIRA E, et al. "Sentinel" circulating tumor cells allow early diagnosis of lung cancer in patients with chronic obstructive pulmonary disease[J]. PLoS One, 2014, 9(10):e111597.
[35] CHEN X X, ZHOU F, LI X F, et al. Folate receptor-positive circulating tumor cell detected by lt-pcr-based method as a diagnostic biomarker for non-small-cell lung cancer[J]. J Thorac Oncol, 2015, 10(8):1163-1171.
[36] NAITO T, TANAKA F, ONO A, et al. Prognostic impact of circulating tumor cells in patients with small cell lung cancer[J]. J Thorac Oncol, 2012, 7(3):512-519.
[37] ANKENY J S, COURT C M, HOU S, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer[J]. Br J Cancer, 2016, 114(12):1367-1375.
[38] QIAO G L, QI W X, JIANG W H, et al. Prognostic significance of circulating tumor cells in esophageal carcinoma:a meta-analysis[J]. Oncol Targets Ther, 2016, 9:1889-1897.
[39] HELLER G, MCCORMACK R, KHEOH T, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer:a comparison with prostate-specific antigen across five randomized phase Ⅲ clinical trials[J]. J Clin Oncol, 2018, 36(6):572-580.
[40] SHIMAZU K, FUKUDA K, YOSHIDA T, et al. High circulating tumor cell concentrations in a specific subtype of gastric cancer with diffuse bone metastasis at diagnosis[J]. World J Gastroenterol, 2016, 22(26):6083-6088.
[41] GEMENETZIS G, GROOT V P, YU J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status:results of the prospective CLUSTER study[J]. Ann Surg, 2018, 268(3):408-420.
[42] SHEN J Q, ZHAO J, JIANG T, et al. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy[J]. Oncotarget, 2017, 8(30):49044-49052.
[43] CHEN J F, HO H, LICHTERMAN J, et al. Subclassification of prostate cancer circulating tumor cells by nuclear size reveals very small nuclear circulating tumor cells in patients with visceral metastases[J]. Cancer, 2015, 121(18):3240-3251.
[44] DE BONO J S, SCHER H I, MONTGOMERY R B, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer[J]. Clin Cancer Res, 2008, 14(19):6302-6309.
[45] SPARANO J, O'NEILL A, ALPAUGH K, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer:a secondary analysis of a randomized clinical trial[J]. JAMA Oncol, 2018, 4(12):1700-1706.
[46] PAPADAKI M A, STOUPIS G, THEODOROPOULOS P A, et al. Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer[J]. Mol Cancer Ther, 2019, 18(2):437-447.
[47] SHEN J, WANG W S, ZHU X L, et al. High epithelial cell adhesion molecule-positive circulating tumor cell count predicts poor survival of patients with unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization[J]. J Vasc Interv Radiol, 2018, 29(12):1678-1684.
[48] PANTEL K, ALIX-PANABIERES C. Functional studies on viable circulating tumor cells[J]. Clin Chem, 2016, 62(2):328-334.
[49] PESTRIN M, BESSI S, PUGLISI F, et al. Final results of a multicenter phase Ⅱ clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study[J]. Breast Cancer Res Treat, 2012, 134(1):283-289.
[50] PACHMANN K, SCHUSTER S. The value of monitoring the behavior of circulating tumor cells at the end of endocrine therapy in breast cancer patients[J]. Cancers (Basel), 2018, 10(11):E407.
[51] GOODMAN C R, SEAGLE B L, FRIEDL T W P, et al. Association of circulating tumor cell status with benefit of radiotherapy and survival in early-stage breast cancer[J]. JAMA Oncol, 2018, 4(8):e180163.
[52] SCHER H I, GRAF R P, SCHREIBER N A, et al. Assessment of the validity of nuclear-localized androgen receptor splice variant 7 in circulating tumor cells as a predictive biomarker for castration-resistant prostate cancer[J]. JAMA Oncol, 2018, 4(9):1179-1186.